Literature DB >> 31526149

Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency.

Xia Wu1, Hui-Lei Miao1, Tie-Nan Zhu1, Jun Feng1, Lu Zhang1, Yue-Ying Mao1, Dao-Bin Zhou1, Xin-Xin Cao1, Jian Li1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31526149     DOI: 10.1080/13506129.2019.1663815

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


× No keyword cloud information.
  1 in total

1.  [Primary light chain amyloidosis onset with acquired FX deficiency: a case report and literature review].

Authors:  C Wei; J Feng; T N Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.